Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest Update

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) was the target of a large growth in short interest in March. As of March 31st, there was short interest totaling 1,834,224 shares, a growth of 126.6% from the March 15th total of 809,588 shares. Based on an average daily trading volume, of 1,429,491 shares, the short-interest ratio is presently 1.3 days. Currently, 15.7% of the shares of the company are sold short.

Reviva Pharmaceuticals Stock Up 12.7%

Shares of NASDAQ RVPH traded up $0.10 during mid-day trading on Monday, reaching $0.87. 707,509 shares of the company were exchanged, compared to its average volume of 479,469. Reviva Pharmaceuticals has a 52 week low of $0.59 and a 52 week high of $23.20. The stock has a market capitalization of $11.13 million, a PE ratio of -0.09 and a beta of 0.64. The company’s 50 day moving average price is $3.15 and its 200 day moving average price is $7.41.

Institutional Trading of Reviva Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC bought a new stake in Reviva Pharmaceuticals in the first quarter worth $58,000. Geode Capital Management LLC lifted its stake in Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the last quarter. XTX Topco Ltd bought a new stake in Reviva Pharmaceuticals in the second quarter worth $31,000. Armistice Capital LLC bought a new stake in Reviva Pharmaceuticals in the second quarter worth $1,026,000. Finally, 683 Capital Management LLC bought a new stake in Reviva Pharmaceuticals in the second quarter worth $381,000. 63.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RVPH shares. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Thursday, January 22nd. D. Boral Capital lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Maxim Group lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 8th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, December 23rd. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $66.67.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.